2018
DOI: 10.1080/14756366.2018.1509210
|View full text |Cite
|
Sign up to set email alerts
|

Novel group of tyrosyl-DNA-phosphodiesterase 1 inhibitors based on disaccharide nucleosides as drug prototypes for anti-cancer therapy

Abstract: A new class of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors based on disaccharide nucleosides was identified. TDP1 plays an essential role in the resistance of cancer cells to currently used antitumour drugs based on Top1 inhibitors such as topotecan and irinotecan. The most effective inhibitors investigated in this study have IC50 values (half-maximal inhibitory concentration) in 0.4–18.5 µM range and demonstrate relatively low own cytotoxicity along with significant synergistic effect in combination wit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
21
0

Year Published

2019
2019
2025
2025

Publication Types

Select...
9

Relationship

3
6

Authors

Journals

citations
Cited by 19 publications
(21 citation statements)
references
References 74 publications
0
21
0
Order By: Relevance
“…This compound is now entering the preclinical trial phase. This group also used semisynthetic derivatives of bile acids and disaccharide nucleosides as a scaffold for the development of Tdp1 catalytic inhibitors [68,69] . The bile acid derivatives were tested by in silico-docking and in a catalytic assay showing inhibition in the 300 to 500 nmol/L ranges with N -(2”-(3’,5’-Di-tret-buthyl-4’-hydroxyphenyl)-ethyl)-3a,12a-diacetoxy-5b-cholan-24-amide as the most promising compound [69] .…”
Section: Catalytic Inhibitorsmentioning
confidence: 99%
“…This compound is now entering the preclinical trial phase. This group also used semisynthetic derivatives of bile acids and disaccharide nucleosides as a scaffold for the development of Tdp1 catalytic inhibitors [68,69] . The bile acid derivatives were tested by in silico-docking and in a catalytic assay showing inhibition in the 300 to 500 nmol/L ranges with N -(2”-(3’,5’-Di-tret-buthyl-4’-hydroxyphenyl)-ethyl)-3a,12a-diacetoxy-5b-cholan-24-amide as the most promising compound [69] .…”
Section: Catalytic Inhibitorsmentioning
confidence: 99%
“…To date, many Tdp1 inhibitors have been identified. A major class of Tdp1 inhibitors comprises those based on natural products including usnic acid derivatives [41][42][43][44][45], coumarins [46], adamantanes [47][48][49], nucleoside analogs [50], dehydroabietylamine derivatives [51], chromenes [52], bile acids derivatives [53], and fungal products [54][55][56]. There are also early reports of Tdp1 inhibition based on diamidines [57], antibiotics [58,59], steroids [60], and other compounds [61].…”
Section: Introductionmentioning
confidence: 99%
“…It has been shown earlier that disaccharide nucleosides with lipophilic groups inhibit Tdp1 in a submicromolar range of concentrations and are only weakly toxic to cancerous and healthy cells [ 19 ]. On the other hand, disaccharide nucleosides tend to inhibit PARP1 [ 20 , 22 ], and this activity may reduce their selectivity toward Tdp1 in the cell.…”
Section: Discussionmentioning
confidence: 99%
“…The literature describes Tdp1 inhibitors of various structures based on different classes of natural and synthetic compounds [ 3 , 4 ]; these inhibitors have half-maximal inhibitory concentrations (IC 50 ) in the range 0.015–10.000 µM. Recently, a novel group of Tdp1 inhibitors effective in the submicromolar range of concentrations was found among disaccharide nucleosides with lipophilic groups [ 19 ]. The current work represents a continuation of our earlier studies on the inhibition of DNA repair enzymes by nucleoside compounds [ 19 , 20 , 21 , 22 , 23 , 24 ].…”
Section: Introductionmentioning
confidence: 99%